Loading quotes...
Forecast
| Buy |
Â
8 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Oncolytics: Preclinical efficacy of Pelareorep in combination with a pan‑RAS inhibitor
Oncolytics reports preclinical data showing that Pelareorep combined with a pan‑RAS inhibitor reduced tumor growth in a RAS‑driven colorectal cancer model during the initial intensive dosing phase. There was no evidence of antagonism between Pelareorep and RAS inhibition, but the additive effect was smaller after switching to weekly Pelareorep dosing. The company plans to evaluate additional dosing schedules and RAS‑driven tumor models. Pelareorep is an intravenous immunotherapy in clinical development and has FDA Fast Track status for several gastrointestinal indications. » More on de.investing.com
FDA dialogue about approval pathway drives Oncolytics Biotech stock
Oncolytics Biotech has announced a "Type D" meeting with the FDA for early August to discuss adding a randomized part B to the REO 033 study, intended to support both accelerated and full approvals for pelareorep. Part B would retain the existing study design, increase the number of participants and incorporate a blinded independent central review to generate randomized efficacy data without starting a separate trial. The company reports progress in part A (target: 60 patients): about half of the sites are expected to be activated by the end of July and more than 20 patients have been pre-identified; full site activation is planned by the end of August. Oncolytics expects a first tumor response update from part A by the end of 2026 and, subject to FDA feedback, aims to begin recruitment for part B in the first quarter of 2027. » More on de.investing.com
Oncolytics schedules FDA Type C meeting on approval pathway for pelareorep in anal cancer
Oncolytics has set a Type C meeting with the FDA for April 16 to discuss a registration‑relevant, single‑arm study plan for pelareorep plus a checkpoint inhibitor in squamous cell carcinoma of the anus in second‑line and later therapy. The planned study would include around 60–70 patients with objective response rate (ORR) as the primary endpoint; earlier data (GOBLET cohort 4) showed an ORR of ~30% with a median duration of response of 17 months versus real‑world rates of 10–14%. The company has a market capitalization of USD 111.52 million, reported a negative free cash flow of USD 26.48 million over the past twelve months, and is given a weak financial rating by InvestingPro. » More on de.investing.com
Oncolytics Biotech completes first step in relocating its registered office to British Columbia
Oncolytics Biotech has completed the first part of its planned relocation and moved its jurisdiction of incorporation from Alberta to British Columbia via a process described as a “continuance.” The common shares, company name and NASDAQ trading symbol remain unchanged; the CUSIP and ISIN will remain the same until the completion of the second phase. Shareholders approved the move on January 15, 2026; the second phase foresees a transfer to Nevada effective March 31, 2026, after which the CUSIP and ISIN will change and outstanding shares will be converted into U.S. par value shares. The company adopted new articles of incorporation in British Columbia that differ in part from its previous founding documents. » More on de.investing.com
FDA grants Fast-Track for Pelareorep — Oncolytics stock jumps sharply
The FDA has granted Fast Track status to Oncolytics' Pelareorep for treatment of metastatic colorectal cancer with KRAS mutation and MSS in the second-line setting. Clinical data showed an objective response rate of 33% vs about 10% for standard therapies, as well as significantly better median PFS and OS. Oncolytics plans a controlled study starting in March, with first interim results expected by the end of 2026; the addressable market is estimated at USD 3–5 billion annually. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -15.01k | - |
| Net profit | -8.57m | 35.31% |
| EBITDA | -8.6m | 44.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €31.03m |
Number of shares | 100.36m |
52-week high/low | €1.18 - €0.31 |
| Dividends | No |
Beta | 1.24 |
P/E ratio | -1.21 |
PEG ratio | 0.26 |
P/B ratio | -5.79 |
P/S ratio | 0.00 |
Company profile
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
| Name | Oncolytics Biotech |
| CEO | Jared Kelly |
| Headquarters | San Diego,
ca Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/10/2001 |
| Employees | 29 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Toronto Stock Exchange | ONC.TO |
NASDAQ | ONCY |
Frankfurt | ONYN.F |